Stockscreener 앱 받기
12.88
1.02%
0.13
시간 외 거래:
12.89
0.010
+0.08%
전일 마감가:
$12.75
열려 있는:
$12.72
하루 거래량:
327.65K
Relative Volume:
0.83
시가총액:
$461.81M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+10.94%
1개월 성능:
+60.80%
6개월 성능:
+186.86%
1년 성능:
+180.61%
1일 변동 폭
$12.55
$13.06
1주일 범위
$11.05
$13.10
52주 변동 폭
$2.88
$13.10
Bioage Labs Inc Stock (BIOA) Company Profile
명칭
Bioage Labs Inc
전화
510-806-1445
주소
5885 HOLLIS STREET, EMERYVILLE
BIOA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
12.88 | 457.15M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2024-12-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-21 | 개시 | Citigroup | Buy |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-21 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
Morgan Stanley Upgrades BioAge Labs (BIOA) - Nasdaq
BioAge Labs (BIOA) Competitors and Alternatives 2025 - MarketBeat
Volume Recap: How BioAge Labs Inc stock reacts to Fed rate cutsFed Meeting & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
BioAge Labs CMO Paul D. Rubin Sells All Common Stock Holdings - TradingView
Officer Rubin Sells 68,897 ($701.9K) Of BioAge Labs Inc [BIOA] - TradingView
BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data - Investing.com South Africa
How BioAge Labs Inc. stock reacts to Fed rate cutsShort Setup & Fast Gain Stock Trading Tips - Newser
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial - Investing.com Nigeria
Is BioAge Labs Inc. stock a safe haven assetQuarterly Earnings Summary & Safe Entry Zone Identification - Newser
Why BioAge Labs Inc. stock remains undervaluedCEO Change & Smart Money Movement Alerts - Newser
How BioAge Labs Inc. (Y7G) stock stacks up against competitorsInsider Selling & Daily Chart Pattern Signal Reports - Newser
Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs - TipRanks
Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Officer Rubin Files To Sell 68,897 Of BioAge Labs Inc [BIOA] - TradingView
Will BioAge Labs Inc. (Y7G) stock outperform global peersCEO Change & Safe Capital Investment Plans - Newser
Merger Talk: Is BioAge Labs Inc stock a safe haven assetPortfolio Growth Summary & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues - marketscreener.com
BioAge Reports Positive Interim Phase 1 Data For BGE-102; Shares Rise - Nasdaq
BioAge Labs Announces Positive Phase 1 Trial Results - TipRanks
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - markets.businessinsider.com
BioAge Labs, Inc. Announces Positive Interim Phase 1 Data for BGE-102 - TradingView
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial By Investing.com - Investing.com South Africa
Is BioAge Labs Inc. (Y7G) stock a buy before new product rolloutJuly 2025 Outlook & Long Hold Capital Preservation Plans - Newser
Is BioAge Labs Inc. (Y7G) stock bottoming after sell off2025 Major Catalysts & Daily Volume Surge Trade Alerts - Newser
BioAge Labs announces positive phase 1 trial results - MSN
Bioage Labs (BIOA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is BioAge Labs Inc. (Y7G) stock supported by free cash flowVolume Spike & Fast Moving Stock Watchlists - Newser
Jefferies Financial Group Inc. Buys Shares of 50,000 BioAge Labs, Inc. $BIOA - MarketBeat
What analysts say about BioAge Labs Inc Y7G stockFibonacci Extensions & Rapid Capital Trading Tips - earlytimes.in
Dhanalaxmi Roto Spinners Limited Stock Analysis Technical Signals for YEARCash Flow Trends & Invest With Confidence - earlytimes.in
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - Sahm
Recent uptick might appease BioAge Labs, Inc. (NASDAQ:BIOA) institutional owners after losing 55% over the past year - Yahoo Finance
Is BioAge Labs Inc a good long term investmentCapital Gains Strategies & Small Budget Portfolio Growth - earlytimes.in
BioAge stock craters 70% on obesity drug study halt (update) - MSN
Is BioAge Labs Inc. stock recession proofStop Loss & Free Weekly Watchlist of Top Performers - newser.com
Will BioAge Labs Inc. (Y7G) stock hit analyst forecastsBuy Signal & Expert Curated Trade Ideas - newser.com
BioAge Labs (BIOA) Price Target Increased by 20.83% to 9.86 - MSN
Is BioAge Labs Inc. (Y7G) stock a buy on weakness2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
How interest rate cuts could boost BioAge Labs Inc. stock2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Is BioAge Labs Inc. stock a buy before product launchesMarket Volume Report & Weekly Top Stock Performers List - newser.com
Bioage Labs Inc (BIOA) 재무 분석
Bioage Labs Inc (BIOA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.48%
0.09%
자본화:
|
볼륨(24시간):